Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Low, Nancy CP"'
Autor:
Low Nancy CP, Dugas Erika, Constantin Evelyn, Karp Igor, Rodriguez Daniel, O’Loughlin Jennifer
Publikováno v:
BMC Psychiatry, Vol 12, Iss 1, p 188 (2012)
Abstract Background Parental history of mood or anxiety disorders is one of the strongest and most consistent risk factors for the development of these disorders in offspring. Gaps remain however in our knowledge of whether maternal or paternal disor
Externí odkaz:
https://doaj.org/article/81adbb11b1df4780a648e90343229c96
Autor:
Low Nancy CP, Dugas Erika, O’Loughlin Erin, Rodriguez Daniel, Contreras Gisele, Chaiton Michael, O’Loughlin Jennifer
Publikováno v:
BMC Psychiatry, Vol 12, Iss 1, p 116 (2012)
Abstract Background Stressful life events are associated with mood disorders in adults in clinical settings. Less described in the literature is the association between common life stressors and a wide range of psychopathology in young adolescents. T
Externí odkaz:
https://doaj.org/article/d6c0979f10ac4ac2bcc9d9c06e052896
Autor:
Hardy John, Low Nancy CP
Publikováno v:
BMC Psychiatry, Vol 7, Iss 1, p 1 (2007)
Abstract Background The advent of standardized classification and assessment of psychiatric disorders, and considerable joint efforts among many countries has led to the reporting of international rates of psychiatric disorders, and inevitably, their
Externí odkaz:
https://doaj.org/article/77ec57e2d7c2435487219e013d73f046
Autor:
Fotso Soh, Jocelyn, Torres-Platas, Susana G., Beaulieu, Serge, Mantere, Outi, Platt, Robert, Mucsi, Istvan, Saury, Sybille, Renaud, Suzane, Levinson, Andrea, Andreazza, Ana C., Mulsant, Benoit H., Müller, Daniel, Schaffer, Ayal, Dols, Annemiek, Cervantes, Pablo, Low, Nancy CP, Herrmann, Nathan, Christensen, Birgitte M., Trepiccione, Francesco, Rajji, Tarek
Publikováno v:
BMC Psychiatry; 7/16/2018, Vol. 18 Issue 1, pN.PAG-N.PAG, 1p, 1 Diagram, 2 Charts
Autor:
Annemiek Dols, Istvan Mucsi, Ana Cristina Andreazza, Daniel J. Müller, Jocelyn Fotso Soh, Nathan Herrmann, Birgitte Mønster Christensen, Robert W. Platt, Soham Rej, Susana G. Torres-Platas, Andrea Levinson, Suzane Renaud, Serge Beaulieu, Outi Mantere, Tarek K. Rajji, Ayal Schaffer, Benoit H. Mulsant, Francesco Trepiccione, Nancy Low, Sybille Saury, Pablo Cervantes
Publikováno v:
Fotso Soh, J, Torres-Platas, S G, Beaulieu, S, Mantere, O, Platt, R, Mucsi, I, Saury, S, Renaud, S, Levinson, A, Andreazza, A C, Mulsant, B H, Müller, D, Schaffer, A, Dols, A, Cervantes, P, Low, N C, Herrmann, N, Christensen, B M, Trepiccione, F, Rajji, T & Rej, S 2018, ' Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus : the protocol of a randomized controlled trial ', BMC Psychiatry, vol. 18, no. 1, 227 . https://doi.org/10.1186/s12888-018-1793-9, https://doi.org/10.1186/s12888-018-1793-9
BMC Psychiatry, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Psychiatry, 18(1):227. BioMed Central
Fotso Soh, J, Torres-Platas, S G, Beaulieu, S, Mantere, O, Platt, R, Mucsi, I, Saury, S, Renaud, S, Levinson, A, Andreazza, A C, Mulsant, B H, Müller, D, Schaffer, A, Dols, A, Cervantes, P, Low, N C, Herrmann, N, Christensen, B M, Trepiccione, F, Rajji, T & Rej, S 2018, ' Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus : the protocol of a randomized controlled trial ', BMC Psychiatry, vol. 18, no. 1, 227 . https://doi.org/10.1186/s12888-018-1793-9
BMC Psychiatry
BMC Psychiatry, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Psychiatry, 18(1):227. BioMed Central
Fotso Soh, J, Torres-Platas, S G, Beaulieu, S, Mantere, O, Platt, R, Mucsi, I, Saury, S, Renaud, S, Levinson, A, Andreazza, A C, Mulsant, B H, Müller, D, Schaffer, A, Dols, A, Cervantes, P, Low, N C, Herrmann, N, Christensen, B M, Trepiccione, F, Rajji, T & Rej, S 2018, ' Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus : the protocol of a randomized controlled trial ', BMC Psychiatry, vol. 18, no. 1, 227 . https://doi.org/10.1186/s12888-018-1793-9
BMC Psychiatry
Introduction Lithium is the gold-standard treatment for bipolar disorder, is highly effective in major depressive disorder, and is being investigated for therapeutic benefits in dementia, stroke, and even cancer. Approximately 350,000 Canadians use l